Solventum, an American healthcare company spun off from 3M in 2024, has completed the sale of its purification and filtration business to Thermo Fisher Scientific for approximately USD 4 billion in cash, subject to customary adjustments, effective 1 September 2025.

The divested business is a leading global provider of purification and filtration technologies used in the production of biologics, as well as in medical technologies and industrial applications. It operates worldwide, with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.

Paksoy is pleased to announce that a team led by partner Stéphanie Beghe Sönmez and associates Meriç Saçak Albaş and Cansın Taner acted as Turkish counsel to Solventum, alongside Cleary Gottlieb Steen & Hamilton, which served as global counsel on this multijurisdictional transaction.

Share


Legal Information

This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.


You May Be Interested In

Privacy Preference Center